The Pharmacoeconomics of Breakthrough Cancer Pain

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 27, Issue 2, 2013, Pages 167-175

  Kuo, Kuan Ling ^a   Saokaew, Surasak ^b,c,d   Stenehjem, David D ^e  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF PHAYAO   (Thailand)

^c NARESUAN UNIVERSITY   (Thailand)

^d Faculty of Medicine Chiang Mai University   (Thailand)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

Breakthrough pain; Cancer; Outcomes; Pharmacoeconomics; Rapid onset opioids

Indexed keywords

FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; MORPHINE SULFATE; OPIATE; OXYCODONE; PLACEBO;

CANCER PAIN; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; HEALTH CARE UTILIZATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INSURANCE; MEDICAL DECISION MAKING; MEDLINE; PHYSICIAN; REVIEW; SOCIETY; TREATMENT OUTCOME;

EID: 84879368894     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2013.787137     Document Type: Review

References (40)

1. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-338.
2. HaugenDF, HjermstadMJ, HagenN, Caraceni A, Kaasa S. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476-482.
3. Skinner C TE, Davies A. Cancer-Related Breakthrough Pain. Oxford, UK: Oxford University Press; 2006.
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206.
5. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
6. Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care. 1998;15:13-22.
7. Hanks GW PR, MacDonald N, Forbes K. Oxford Textbook of Pallitative Medicine. New York: Oxford University Press; 1998.
8. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.
9. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263-274.
10. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain SymptomManage. 2003;25:9-18.
11. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.
12. Webber K, Davies AN, Cowie MR. Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer. 2011;19:2041-2046.
13. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-e68.
14. Ruiz-Garcia V, Lopez-Briz E. Morphine remains gold standard in breakthrough cancer pain. BMJ. 2008;337:a3104.
15. McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007;8(Suppl 1):S8-S13.
16. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: HYPERLINK "http://www.cearegistry.org" www.cearegistry.org. Accessed on [2012.08.23].
17. Llanes LR, Fassbender K, Baracos VE, Watanabe S. Drug utilization review on a tertiary palliative care unit. J Pain Symptom Manage. 2006;31:457-464.
18. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12:1040-1046.
19. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet. 1991;337:465-468.
20. Grant M, Ferrell BR, Rivera LM, Lee J. Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Nurs Clin North Am. 1995;30:673-682.
21. Fortner BV, Okon TA, Ashley J, et al. The Zero Acceptance of Pain (ZAP)TM Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain SymptomManage. 2003;25:334-343.
22. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38-44.
23. Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011;14:274-281.
24. Abernethy AP, Samsa GP, Matchar DB. A clinical decision and economic analysis model of cancer pain management. Am J Manag Care. 2003;9:651-664.
25. Rascati KL. Essentials of Pharmacoeconomics. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
26. Doolittle GC, Harmon A, Williams A, et al. A cost analysis of a tele-oncology practice. J Telemed Telecare. 1997;3(Suppl 1):20-22.
27. Ferrell BR, Griffith H. Cost issues related to pain management: report from theCancer Pain Panel of the Agency for HealthCare Policy and Research. J Pain Symptom Manage. 1994;9:221-234.
28. Williams RM.Distribution of emergency department costs. Ann Emerg Med. 1996;28:671-676.
29. Gunnar B. Statistical Estimates and Transformed Beta-Variables. New York: John Wiley and Sons; 1958.
30. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210.
31. Jacox ACD, Payne R, Berde CB, Breitbart W, Cain JM, eds. Clinical Practice Guideline No. 9. Management of Cancer Pain. Rockville, MD: Agency for Health Care Policy and Research; 1994.
32. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30:1980-1988.
33. Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care. 2008;14(5 Suppl 1):S129-S140.
34. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.
35. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-334.
36. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebocontrolled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-1191.
37. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805-2815.
38. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-616.
39. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123-130.
40. Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, doubleblind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224-231.